Skip to search formSkip to main contentSkip to account menu

Ku 0063794

Known as: Ku-63794, Ku 63794, Ku -0063794 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

MorpholinesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Role of mTOR signaling in the regulation of high glucose-induced podocyte injury
Podocyte injury, which promotes progressive nephropathy, is considered a key factor in the progression of diabetic nephropathy… 
2017
2017
The TOR Pathway Is Involved in Adventitious Root Formation in Arabidopsis and Potato
In the agriculture industry, adventitious root formation is a core issue of plants asexual propagation. However, the underlying… 
2017
2017
Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition.
2017
2017
Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy
Purpose Everolimus only inhibits mammalian target of rapamycin complex 1 (mTORC1), whereas Ku0063794 inhibits both mTORC1 and… 
2016
2016
mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA…
Recent studies have identified a role for supraphysiological gamma-aminobutyric acid (GABA) in the regulation of mechanistic… 
2014
2014
Short term exposure to elevated levels of leptin reduces proximal tubule cell metabolic activity
2014
2014
Differential Role of Rapamycin and Torin/KU63794 in Inflammatory Response of 264.7 RAW Macrophages Stimulated by CA-MRSA
Background. Rapamycin suppresses the RAW264.7 macrophage mediated inflammatory response but in lower doses induces it. In the… 
2013
2013
Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells
Aims Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown dramatic clinical benefits in advanced… 
2012
2012
300 A COMPARISON OF KU0063794, A DUAL MTORC1 AND MTORC2 INHIBITOR, AND TEMSIROLIMUS IN PRECLINICAL RENAL CELL CARCINOMA MODELS
2009
2009
Activating Mutations in TOR Are in Similar Structures As Oncogenic Mutations in PI3KCα
TOR (Target of Rapamycin) is a highly conserved Ser/Thr kinase and a central controller of cell growth. Using the crystal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)